Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Deferred Taxes: 2020-2024

Historic Deferred Taxes for Catalyst Pharmaceuticals (CPRX) over the last 5 years, with Dec 2024 value amounting to $9.4 million.

  • Catalyst Pharmaceuticals' Deferred Taxes fell 128.16% to -$2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$217,000, marking a year-over-year decrease of 101.96%. This contributed to the annual value of $9.4 million for FY2024, which is 47.31% down from last year.
  • Catalyst Pharmaceuticals' Deferred Taxes amounted to $9.4 million in FY2024, which was down 47.31% from $17.8 million recorded in FY2023.
  • Over the past 5 years, Catalyst Pharmaceuticals' Deferred Taxes peaked at $33.0 million during FY2020, and registered a low of -$9.3 million during FY2021.
  • Moreover, its 3-year median value for Deferred Taxes was $9.4 million (2024), whereas its average is $7.4 million.
  • In the last 5 years, Catalyst Pharmaceuticals' Deferred Taxes crashed by 128.26% in 2021 and then spiked by 460.91% in 2023.
  • Yearly analysis of 5 years shows Catalyst Pharmaceuticals' Deferred Taxes stood at $33.0 million in 2020, then tumbled by 128.26% to -$9.3 million in 2021, then soared by 47.01% to -$4.9 million in 2022, then spiked by 460.91% to $17.8 million in 2023, then slumped by 47.31% to $9.4 million in 2024.